topotecan

P1, N=50, Not yet recruiting, Massachusetts Eye and Ear Infirmary | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Dec 2026

P3, N=686, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Oct 2028 --> Jun 2028 | Trial primary completion date: Oct 2028 --> Jun 2028

CPT-01 demonstrates enhanced anti-tumor efficacy and reduced toxicity compared to TPT, offering promising clinical potential for liver cancer treatment.

P2/3, N=260, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed

P3, N=1080, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting

Low-risk patients were enriched in fatty acid metabolism and peroxisome pathways, exhibited higher immunotherapy responsiveness, and showed greater sensitivity to Gefitinib and Afatinib. High-risk patients exhibited activation of inflammatory and profibrotic pathways, an elevated TMB, immunosuppressive microenvironments, and greater sensitivity to Topotecan and Irinotecan. RT-qPCR validated the expression of HGRGs across selected cell lines. The prognostic model derived from five HGRGs demonstrates excellent clinical value in predicting prognosis and guiding therapeutic strategies in KIRC.

The patient was treated with systemic conventional and high-dose chemotherapy combined with intrathecal Topotecan. This case suggests that anti-GD2 immunotherapy, used as consolidation treatment, may improve the prognosis of patients with advanced retinoblastoma and potentially reduce the toxicity associated with standard therapies. Further clinical investigation is warranted to validate these findings.

Dna2 mutants demonstrated significant sensitivity to replication stress induced by MMS, hydroxyurea, topotecan, and nitrogen mustard. Dna2lS/S1 mutants exhibited higher survival than Dna2lS/D2 upon exposure to topotecan and bleomycin, suggesting a possible helicase-specific role in damage response...These insights clarify the nuanced contributions of the nuclease and helicase domains of DNA2, suggesting potential domain-specific functions in genomic stability and repair mechanisms. This work provides a foundation that will enable future researchers to further dissect the complex roles of DNA2 in replication and repair pathways.

P3, N=540, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting

P3, N=530, Recruiting, Genmab | Trial primary completion date: May 2027 --> Feb 2027

P3, N=1100, Not yet recruiting, AstraZeneca

P2, N=106, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Sep 2025